脊髄性筋萎縮症:アジア太平洋市場予測2028

◆英語タイトル:Spinal Muscular Atrophy: Forecast in Asia-Pacific Markets to 2028
◆商品コード:GDT20FB0246
◆発行会社(リサーチ会社):GlobalData
◆発行日:2019年11月
◆ページ数:104
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD8,995 ⇒換算¥953,470見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD17,990 ⇒換算¥1,906,940見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD26,985 ⇒換算¥2,860,410見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Spinal Muscular Atrophy: Forecast in Asia-Pacific Markets to 2028
Summary

Spinal muscular atrophy (SMA) is a rare genetic neurodegenerative disease that primarily affects children. It is characterized by loss of spinal motor neurons, which are specialized cells that control muscle movement.

In recent years the first approved therapy for SMA, Biogen’s Spinraza (nusinersen), has gained marketing authorization in four of the five growth markets (5GM) – Japan, Australia, South Korea and China.

Strong market growth is anticipated across the 5GM over the forecast period. This will largely be driven by increased uptake of Spinraza in the early-to-mid forecast period and the launch of pipeline products from 2020 onwards.

Key unmet environmental and clinical needs in SMA include limited SMA resources and specialists, lack of disease awareness among physicians, low diagnosis rates, limited treatment options and lack of access to disease-modifying therapy for late-onset SMA.

Key Questions Answered
- How is SMA currently managed and does this vary by subtype?
- To what extent will the launch of pipeline products over the forecast period fulfil the unmet needs in the market?
- How will the launch of pipeline products impact Spinraza?
- How will growth vary by market?

Key Highlights

- In the past three years, Spinraza, the first disease-modifying therapy for SMA has been approved in four of the 5GM – Japan, Australia, South Korea and China.
- However, the market remains characterized by significant unmet needs, both clinical (e.g. limited treatment options) and environmental (e.g. lack of disease awareness among physicians).
- GlobalData anticipates that four pipeline drugs will launch over the forecast period in the Asia-Pacific (APAC) region. These pipeline drugs are expected to address significant unmet needs for SMA and significantly boost growth in the SMA market across the 5GM.
- These pipeline products include Novartis’ Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy administered as a one-time intravenous infusion, as well as risdiplam and branaplam, orally administered small molecules in development by Roche and Novartis, respectively, which have a similar mechanism of action to Spinraza.
- Across the 5GM, the SMA market is projected to grow from $308.6M in 2018 to $2.5B in 2018 at a CAGR of 23.3%.

Scope

- Overview of SMA, including epidemiology, etiology, pathophysiology, classification, diagnosis, and disease management.
- Market Data including annualized SMA therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in fours patient segments (Type 1, 2, 3, and 4) forecast from 2018 to 2028.
- Key topics covered include unmet needs and opportunity assessment, R&D strategies and clinical trial design.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for SMA therapy. The most promising candidates in Phase II and III development are profiled.
- Analysis of the current and future market competition in the SMA therapeutics market: Insightful review of the industry drivers and barriers and in-depth analysis of trends within each of the 5GM.

Reasons to buy

The report will enable you to –
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies most active within the SMA APAC landscape.
- Develop business strategies by understanding the trends shaping and driving the SMA APAC market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the SMA APAC market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

【レポートの目次】

Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Spinal Muscular Atrophy: Executive Summary
2.1 Uptake of New Products to Drive Robust Growth Within the SMA Market
2.2 Biogen to Lose its Monopoly of the SMA Market
2.3 Unmet Needs Remain High Despite Approval of First Disease-Modifying Therapy
2.4 Zolgensma and Risdiplam Demonstrate Greatest Potential in SMA
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.2 Forecast Assumptions and Methods
5.4.3 Forecast Assumptions and Methods – Diagnosed Prevalent Cases of SMA
5.5 Epidemiological Forecast for SMA for Growth Markets (2018-2028)
5.5.1 Diagnosed Prevalent Cases of SMA
5.5.2 Sex-Specific Diagnosed Prevalent Cases of SMA
5.5.3 Diagnosed Prevalent Cases of SMA by Type
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis
6 Current Treatment Options
6.1 Overview
7 Unmet Needs and Opportunity Assessment in APAC
8 R&D Strategies in APAC
9 Pipeline Assessment in APAC
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Pipeline Valuation Analysis
11 Appendix

List of Tables
Table 1: SMA: Key Metrics in the 5GM in APAC
Table 2: Clinical Classification of SMA
Table 3: Risk Factors and Comorbidities for SMA
Table 4: Treatment Guidelines for SMA
Table 5: Leading Treatments for SMA, 2019
Table 6: Clinical Trials for Zolgensma (Onasemnogene Abeparvovec-xioi), 2019
Table 7: Clinical Trials for Risdiplam, 2019
Table 8: Clinical Trials for Valproate Sodium, 2019
Table 9: Comparison of Therapeutic Classes in Development for SMA, 2018-2028
Table 10: Clinical Benchmark of Key Pipeline Drugs - SMA
Table 11: Commercial Benchmark of Key Pipeline Drugs - SMA
Table 12: Key Events Impacting Sales for SMA, 2018-2028
Table 13: SMA Market - Global Drivers and Barriers, 2018-2028
Table 14: Key Historical and Projected Launch Dates for SMA
Table 15: Key Historical and Projected Patent Expiry Dates for SMA
Table 16: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global Sales Forecast by Country for SMA in 2018 and 2028
Figure 2: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of SMA During the Forecast Period
Figure 3: The Difference Between SMN1 and SMN2 Genes and the Molecular Basis of SMA
Figure 4: Diagnostic Evaluation for SMA
Figure 5: 5GM, Diagnosed Prevalence of SMA, %, Both Sexes, All Ages, 2018
Figure 6: 5GM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of SMA
Figure 7: 5GM, Diagnosed Prevalent Cases of SMA, N, Both Sexes, All Ages, 2018
Figure 8: 5GM, Sex-Specific Diagnosed Prevalent Cases of SMA, N, All Ages, 2018
Figure 9: 5GM, Diagnosed Prevalent Cases of SMA by Type, N, Both Sexes, All Ages, 2018
Figure 10: Unmet Needs and Opportunities in SMA
Figure 11: Overview of the Development Pipeline SMA
Figure 12: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to be Licensed for SMA in the 5GM During the Forecast Period
Figure 13: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Spinraza
Figure 14: 5GM Sales Forecast by Country for SMA in 2018 and 2028
Figure 15: Sales Forecast by Product for SMA in India in 2028
Figure 16: Sales Forecast by Product for SMA in China in 2018 and 2028
Figure 17: Sales Forecast by Product for SMA in Australia in 2018 and 2028
Figure 18: Sales Forecast by Product for SMA in South Korea in 2018 and 2028
Figure 19: Sales Forecast by Products for SMA in Japan in 2018 and 2028

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[脊髄性筋萎縮症:アジア太平洋市場予測2028]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆